Table 1 Baseline characteristics n = 247
Parameter | Number | Percent |
|---|---|---|
Age | ||
 Median (range) | 52 (28–78) |  |
Menopausal Status | ||
 Premenopausal | 111 | 44.9 |
 Perimenopausal | 5 | 2.0 |
 Postmenopausal | 126 | 51.0 |
 Unknown | 5 | 2.0 |
Tumor Size | ||
 cT 1 | 14 | 5.7 |
 cT 2 | 123 | 49.8 |
 cT 3 | 68 | 27.5 |
 cT 4 | 27 | 10.9 |
 Unknown | 15 | 6.1 |
Histology | ||
 ILC | 27 | 10.9 |
 IDC | 194 | 78.5 |
 Mixed | 21 | 8.5 |
 Others | 2 | 0.8 |
 Unknown | 3 | 1.2 |
Tumor Grading | ||
 G1 | 17 | 6.9 |
 G2 | 86 | 34.8 |
 G3 | 122 | 49.4 |
 Unknown | 22 | 8.9 |
Her2 Status | ||
 Negative | 164 | 66.4 |
 Positive | 49 | 19.8 |
 Unknown | 34 | 13.8 |
ER Status | ||
 Negative | 95 | 38.5 |
 Positive | 150 | 60.7 |
 Unknown | 2 | 0.8 |
PR Status | ||
 Negative | 106 | 42.9 |
 Positive | 134 | 54.3 |
 Unknown | 7 | 2.8 |
Lymph node Status | ||
 Negative | 98 | 39.7 |
 Positive | 147 | 59.5 |
 Unknown | 2 | 0.8 |
Neoadjuvant Therapy | ||
 Anthracycline | 81 | 32.8 |
 Anthracycline/Taxane | 144 | 58.3 |
 Taxane | 7 | 2.8 |
 Others | 15 | 6.1 |
No of therapy cycles | ||
 Median (range) | 4 (1–8) |  |
Response to Therapy | ||
 No (Sinn 0) | 75 | 30.4 |
 Yes (Sinn 1–4) | 172 | 69.6 |
pCR | ||
 No (Sinn Score 0,1,2) | 218 | 88.3 |
 Yes (Sinn Score 3,4) | 29 | 11.7 |
pCR | ||
 No (all others) | 216 | 87.4 |
 Yes (Sinn 3 or 4 and pN0) | 21 | 8.5 |
 Unknown | 10 | 4.0 |
Recurrence | ||
 No | 150 | 60.7 |
 Yes | 95 | 38.5 |
 Unknown | 2 | 0.8 |